155 related articles for article (PubMed ID: 21410688)
1. Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart.
Kang W; Elitzer S; Noh K; Bednarek T; Weiss M
Br J Pharmacol; 2011 Aug; 163(8):1733-9. PubMed ID: 21410688
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.
Liu KH; Kim MG; Lee DJ; Yoon YJ; Kim MJ; Shon JH; Choi CS; Choi YK; Desta Z; Shin JG
Drug Metab Dispos; 2006 Nov; 34(11):1793-7. PubMed ID: 16896065
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.
Kang W; Liu KH; Ryu JY; Shin JG
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):75-80. PubMed ID: 15556518
[TBL] [Abstract][Full Text] [Related]
4. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450.
Hashizume T; Mise M; Terauchi Y; O L; Fujii T; Miyazaki H; Inaba T
Drug Metab Dispos; 1998 Jun; 26(6):566-71. PubMed ID: 9616193
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
[TBL] [Abstract][Full Text] [Related]
7. Studies on the first-pass metabolism of ebastine in rats.
Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
Huang MY; Argenti D; Wilson J; Garcia J; Heald D
Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
[TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine.
Tamai I; Kido Y; Yamashita J; Sai Y; Tsuji A
J Drug Target; 2000; 8(6):383-93. PubMed ID: 11328664
[TBL] [Abstract][Full Text] [Related]
11. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
Hashizume T; Imaoka S; Mise M; Terauchi Y; Fujii T; Miyazaki H; Kamataki T; Funae Y
J Pharmacol Exp Ther; 2002 Jan; 300(1):298-304. PubMed ID: 11752129
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.
Vincent J; Liminana R; Meredith PA; Reid JL
Br J Clin Pharmacol; 1988 Nov; 26(5):497-502. PubMed ID: 2905150
[TBL] [Abstract][Full Text] [Related]
16. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants.
Shon JH; Yeo CW; Liu KH; Lee SS; Cha IJ; Shin JG
J Clin Pharmacol; 2010 Feb; 50(2):195-204. PubMed ID: 19841159
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological study of ebastine, a novel histamine H1-receptor antagonist].
Yakuo I; Ishii K; Seto Y; Imano K; Takeyama K; Nakamura H; Karasawa T
Nihon Yakurigaku Zasshi; 1994 Mar; 103(3):121-35. PubMed ID: 7511558
[TBL] [Abstract][Full Text] [Related]
18. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of ebastine in children.
Simons FE; Watson WT; Simons KJ
J Pediatr; 1993 Apr; 122(4):641-6. PubMed ID: 8096545
[TBL] [Abstract][Full Text] [Related]
20. In vivo evidence for a lack of central effect of ebastine, an antihistaminic agent, in rats: a microdialysis study.
Fujisaki Y; Itoh Y; Oishi R
Jpn J Pharmacol; 2002 Dec; 90(4):353-6. PubMed ID: 12501012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
